Market Access News | pharmaphorum

News

FDA clears first genetic hearing loss gene therapy

Regeneron's Otarmeni is the first gene therapy for congenital hearing loss to be cleared by the FDA, and will be made available for free in the US.

News

Trump's DOJ reschedules medicinal marijuana, increasing acce...

The US Justice Department has issued an order moving medical marijuana to Schedule III, removing some barriers to access for patients and researchers.

News

AbbVie makes record investment in North Carolina plant

AbbVie's $100bn programme of facility investments in the US has continued with a new 185-acre campus in Durham, North Carolina.

News

FDA delays decision on Sanofi's subcutaneous Sarclisa

The FDA has extended its review of a new version of Sanofi's multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex.

News

Medicare obesity drug pilot extended after insurer pushback

Medicare will cover the cost of a pilot of weight-loss drug coverage, after health insurers refuse to take part.

News

Jazz and Lilly cancer drugs cleared for use by NHS

Jazz's biliary tract cancer drug Ziihera and Lilly's Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.

FDA clears first genetic hearing loss gene therapy

Trump's DOJ reschedules medicinal marijuana, increasing acce...

AbbVie makes record investment in North Carolina plant

FDA delays decision on Sanofi's subcutaneous Sarclisa

Medicare obesity drug pilot extended after insurer pushback

Jazz and Lilly cancer drugs cleared for use by NHS

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks